Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyModa Health TMS Prior Auth Update | OpenPayer
    Ask Trek AI about this page
    CurrentModa HealthPolicy N/A

    Transcranial Magnetic Stimulation (TMS)

    Customize your policy alerts

    Sign up for all Moda Health policy alerts

    Know when Moda Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs Moda Health medical-necessity and prior-authorization requirements for TMS, including repetitive and deep TMS, for treatment-resistant severe major depressive disorder and obsessive-compulsive disorder. It applies to providers requesting initiation, continuation beyond 36 sessions, or reintroduction of TMS.

    Policy Summary
    PayerModa Health
    PolicyTranscranial Magnetic Stimulation (TMS)
    Policy CodePolicy N/A
    Change TypeAnnual reviewreintroduction criteria added
    Effective DateNovember 1, 2026
    Last ReviewOct 28, 2026
    Next Review DateN/A
    Key ActionSubmit the psychiatric evaluation, supporting chart documentation, standardized symptom-rating results, safety screening, and requested CPT codes, units, and date span with the prior-authorization request.
    SourceLink
    POLICY UPDATE CHANGES

    The October 2026 annual review added criteria for reintroducing TMS after completion of an acute treatment episode.

    15+Minimum age for depression treatment
    18+Minimum age for OCD treatment
    36 sessionsStandard acute course
    2 indications

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered treatment-resistant conditions
    50% / 30%Reintroduction response thresholds
    ExperimentalMaintenance TMS coverage stance

    Coverage Criteria

    Initiation Criteria

    Authorization for initiation of transcranial magnetic stimulation (TMS) is indicated when ALL of the following criteria are met.

    ALL of the following

    • The device has FDA approval for the intended use.
    • The patient is age 15 or older for treatment of depression; age 18 or older for treatment of obsessive-compulsive disorder (OCD).
    • ONE of the following indications

      • Treatment-resistant severe major depressive disorder

        • The patient has a confirmed diagnosis of treatment-resistant severe major depressive disorder, single episode or recurrent.
        • Results of a standardized, evidence-based depression rating scale reliably measure depressive symptoms.
        • The onset of the current episode and history of any previous episodes are identified.
        • Differential diagnosis has been completed, and another diagnosis, such as depressive disorder due to another medical condition, does not better account for the patient's symptoms.
        • Adequate pharmacological treatment trials

          • The patient has had adequate trials of pharmacological treatments with less than a 50% reduction in symptoms, as documented on a standardized measurement tool.
          • At least two different antidepressant agents were tried concurrently or separately with adequate dose and duration, or were discontinued due to intolerable side effects.
          • At least one antidepressant agent was tried for at least six weeks, unless none of the agents was tolerated.>= 6 weeks
          • Documentation of the drug trials includes doses, duration, side effects, augmentations, and response.
        • Adequate evidence-based psychotherapy trial

          • The patient has had an adequate trial of evidence-based psychotherapy within the current depressive episode.
          • Documentation describes the psychotherapy modality, frequency, and duration.
          • Documentation shows inadequate response, generally including less than a 50% reduction in symptoms using a standardized measurement tool.
      • Treatment-resistant severe obsessive-compulsive disorder

        • The patient has a confirmed diagnosis of treatment-resistant severe obsessive-compulsive disorder.
        • Results of a standardized, evidence-based OCD rating scale are documented.
        • Symptomatology and relevant history are described.
        • Adequate pharmacological treatment trials

          • The patient has had adequate trials of pharmacological treatments with less than a 30% reduction in symptoms, as documented on a standardized measurement tool.
          • At least two different agents were tried concurrently or separately with adequate dose and duration, or were discontinued due to intolerable side effects.
    • The treating provider has ruled out contraindications such as active substance use disorder, seizure disorder, or any medications, implants, or devices that may compromise the safety or efficacy of the procedure. The Transcranial Magnetic Stimulation Adult Safety Screen (TASS) may be used to assess an individual's safety for TMS.

    Continued Care Criteria

    Authorization extending a standard course of TMS beyond 36 sessions is indicated when ALL of the following criteria are met.

    ALL of the following

    • The patient has shown a positive response to treatment, as evidenced by a reduction in depressive symptoms on a standardized measurement tool.
    • Additional visits are needed due to a need for re-mapping or other confounding factors.
    • The treatment plan includes a plan for completing treatment with the lowest appropriate number of additional sessions.

    Reintroduction Criteria

    Authorization for reintroducing TMS after completion of an acute episode of treatment is indicated when ALL of the following criteria are met.

    ALL of the following

    • The patient met the guidelines for initial treatment.
    • The patient responded positively to the previous course of TMS, as evidenced by at least 50% improvement in depressive symptoms or at least 30% improvement in OCD symptoms, measured by a standardized instrument.Depression: >= 50% improvement; OCD: >= 30% improvement
    • Sufficient time has elapsed since completion of treatment to establish a clinically meaningful increase in symptoms.
    • The patient's symptoms have worsened, as evidenced by a 50% or greater increase from peak response, measured by the same standardized instrument used in the previous treatment.>= 50% increase from peak response

    The role of follow-up or maintenance treatment has not been established in the literature, and there is not yet a generally accepted protocol for maintenance treatment. Due to the paucity of high-quality evidence and lack of expert agreement on maintenance protocols, maintenance TMS is generally considered experimental/investigational.

    Administration of standard symptom inventories such as the Y-BOCS, PHQ-9, or HAM-D is a routine component of assessing appropriateness for TMS and response to treatment. Administration of these symptom inventories in this context is not psychological testing and may not be billed with CPT codes 96130-96139.

    Coding and Clinical Thresholds

    CPT or HCPC codes coveredCPTCovered
    90867Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management.
    90868Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session
    90869Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold redetermination with delivery and management.
    Applicable ICD-10 diagnosis codesICD-10
    F33.2Major depressive disorder, Recurrent, Severe.
    F32.2Major depressive disorder, Single episode, Severe.
    F42Obsessive-compulsive disorder
    Billing limitation for symptom inventoriesCPTNot Covered
    96130-96139Psychological testing CPT codes; standard symptom inventories used for TMS appropriateness and response are not psychological testing and may not be billed with these codes in this context.
    Depression medication response
    Depression medication responseLess than 50% reduction in symptoms on a standardized measurement tool
    Medication trialsAt least two different antidepressant agents with adequate dose and duration, or discontinued because of intolerable side effects
    DurationAt least six weeks for one or more antidepressant agents, unless none was tolerated
    OCD medication and ERP response
    OCD medication and ERP responseLess than 30% reduction in symptoms on a standardized measurement tool
    Medication trials

    Prior Authorization and Documentation

    Documentation Required

    Submit Clinical Records and Requested Services

    Submit the clinical records needed to evaluate medical necessity, along with the requested TMS services and billing details.

    • Psychiatric evaluation chart notes, diagnosis, symptomatology, relevant history, treatment history, substance-use history, and contraindication screening.
    • Standardized evidence-based symptom-rating results.
    • Requested CPT codes, units, and date span.
    Step Therapy

    Document Depression Treatment Trials

    Document adequate medication and psychotherapy trials for treatment-resistant severe major depressive disorder (MDD).

    • At least two different antidepressant agents, used concurrently or separately, at adequate dose and duration or discontinued because of intolerable side effects.
    • At least one antidepressant trial must generally last at least 6 weeks unless no agent was tolerated.

    Background

    Transcranial magnetic stimulation (TMS) is a noninvasive brain-stimulation treatment delivered with a magnetic coil placed against the scalp. Treatment is generally provided in an office setting through daily sessions over several weeks, without anesthesia or induction of a convulsion. A typical course is 5 treatments per week for 6 weeks, followed by a 3-week taper, for 36 treatments total.

    Definitions

    Transcranial magnetic stimulation (TMS)
    Treatment methodA noninvasive method of delivering electrical stimulation to the brain
    Magnetic coilUses a specifically designed magnetic coil placed in contact with the scalp
    Neural stimulationThe coil generates rapidly alternating magnetic fields that produce electrical stimulation of cortical neurons
    Repetitive transcranial magnetic stimulation (rTMS)
    DefinitionA form of TMS that delivers repeated magnetic stimulation
    Relationship to TMSrTMS is included within transcranial magnetic stimulation (TMS)
    Deep TMS

    TMS Treatment Modalities

    Transcranial Magnetic Stimulation (TMS)

    TMS coverage is available under the applicable medical-necessity pathway for initiation, continued care beyond the standard acute course, or reintroduction after a completed acute episode.

    TMS treatment modality: TMS is authorized for FDA-approved treatment of treatment-resistant severe major depressive disorder in patients age 15 or older or treatment-resistant severe obsessive-compulsive disorder in patients age 18 or older, when the applicable medication and psychotherapy or ERP failures, standardized symptom measures, and safety-screening requirements are met.Depression age >=15; OCD age >=18

    Continuation beyond 36 sessions and reintroduction after an acute episode require additional criteria.

    Policy Summary
    PayerModa Health
    PolicyTranscranial Magnetic Stimulation (TMS)
    Policy CodePolicy N/A
    Change TypeAnnual reviewreintroduction criteria added
    Effective DateNovember 1, 2026
    Last ReviewOct 28, 2026
    Next Review DateN/A
    Key ActionSubmit the psychiatric evaluation, supporting chart documentation, standardized symptom-rating results, safety screening, and requested CPT codes, units, and date span with the prior-authorization request.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsPrior Authorization and DocumentationBackgroundDefinitionsTMS Treatment Modalities
    At least one agent was tried for at least six weeks, unless none of the agents was tolerated.>= 6 weeks
  1. Documentation of the drug trials includes doses, duration, side effects, augmentations, and response.
  2. Adequate Exposure and Response Prevention therapy trial

    • The patient has had an adequate trial of Exposure and Response Prevention (ERP) therapy.
    • Documentation describes the ERP modality, frequency, and duration.
    • Documentation shows inadequate response, generally including less than a 30% reduction in symptoms using a standardized measurement tool.
  3. Other treatment approaches, such as psychotherapy, pharmacotherapy, or ERP, are employed concurrently as appropriate.
  4. At least two different agents with adequate dose and duration, or discontinued because of intolerable side effects
    ERP responseAn adequate Exposure and Response Prevention therapy trial must show inadequate response, generally including less than 30% symptom reduction on a standardized measurement tool
    Prior depression response for reintroduction
    Prior depression response50% or better improvement in depressive symptoms
    MeasurementResponse must be measured by a standardized instrument
    Reintroduction requirementThe patient must have responded positively to the previous course of TMS
    Prior OCD response for reintroduction
    Prior OCD response30% or better improvement in OCD symptoms
    MeasurementResponse must be measured by a standardized instrument
    Reintroduction requirementThe patient must have responded positively to the previous course of TMS
    Symptom worsening for reintroduction
    Symptom worsening50% or greater increase from peak response
    MeasurementUse the same standardized instrument used in the previous treatment
    TimingSufficient time must have elapsed since treatment completion to establish a clinically meaningful increase in symptoms
    Standard acute course
    Total course36 treatments total
    Initial scheduleFive treatments per week for six weeks, totaling 30 sessions
    TaperA three-week taper follows: three treatments in week one, two in week two, and one in week three
  5. Record doses, duration, side effects, augmentations, and response; inadequate pharmacologic response is generally less than a 50% symptom reduction on a standardized measure.
  6. Document an evidence-based psychotherapy trial during the current depressive episode, including modality, frequency, duration, and inadequate response, generally less than a 50% reduction on a standardized measure.
  7. Step Therapy

    Document OCD Medication and ERP Trials

    For treatment-resistant severe obsessive-compulsive disorder (OCD), document adequate medication and exposure and response prevention (ERP) trials before requesting TMS.

    • At least two different agents, used concurrently or separately, at adequate dose and duration or discontinued because of intolerable side effects.
    • At least one medication trial must generally last at least 6 weeks unless no agent was tolerated; record doses, duration, side effects, augmentations, and response.
    • Document ERP modality, frequency, duration, and inadequate response, generally less than a 30% reduction in symptoms on a standardized measure.
    • Pharmacologic inadequate response is generally less than a 30% reduction in symptoms on a standardized measure.
    Documentation Required

    Provide Psychiatric Evaluation and Clinical History

    Provide a psychiatric evaluation that establishes the diagnosis and clinical need for TMS, supported by standardized, evidence-based symptom measurement.

    • Include evaluation chart notes, diagnosis, symptomatology, and results from a standardized evidence-based symptom-rating scale.
    • For depression, document onset of the current episode, previous episodes, and differential diagnosis showing that another medical condition does not better explain symptoms.
    • For OCD, describe symptomatology and relevant history.
    Documentation Required

    Document Prior Treatment Failure

    Show inadequate response to the required medication and psychotherapy or ERP trials using standardized symptom measures and complete treatment documentation.

    • For MDD, document less than a 50% reduction in symptoms after adequate antidepressant and psychotherapy trials.
    • For OCD, document less than a 30% reduction in symptoms after adequate medication and ERP trials.
    • Include treatment dates, modality, frequency, duration, doses, side effects, augmentations, and response.
    Documentation Required

    Complete Safety and Contraindication Screening

    Screen for and document safety issues that could compromise the safety or efficacy of TMS before treatment. The Transcranial Magnetic Stimulation Adult Safety Screen (TASS) may be used for this assessment.

    • Assess for active substance use disorder and seizure disorder.
    • Review medications, implants, and devices that may compromise TMS safety or efficacy.
    • Include documentation of contraindication screening in the prior-authorization records.
    Prior Authorization

    Specify Requested TMS Services

    Include the complete requested-service information with the prior-authorization submission so the requested treatment can be authorized and scheduled.

    • Requested CPT codes.
    • Number of units.
    • Requested date span.
    Denial Risk

    Failure to Meet Initiation Criteria

    TMS initiation may be denied when the requested use does not meet the applicable FDA approval, age, and indication requirements.

    • The device must have FDA approval for the intended use.
    • Patient must be age 15 or older for depression treatment and age 18 or older for OCD treatment.
    • The patient must meet the applicable initiation criteria for treatment-resistant severe MDD or treatment-resistant severe OCD, including required standardized measures and prior-treatment trials.
    Denial Risk

    Maintenance TMS Generally Experimental

    Maintenance TMS is generally considered experimental/investigational because high-quality evidence and an accepted maintenance protocol have not been established.

    • The role of follow-up or maintenance treatment remains uncertain.
    • Requests for routine maintenance treatment may not meet coverage criteria.
    Denial Risk

    Justify Sessions Beyond 36

    Requests to extend a standard course beyond 36 sessions may be denied unless all continued-care requirements are documented.

    • The patient has shown a positive response, evidenced by reduced depressive symptoms on a standardized measure.
    • Additional sessions are needed because of re-mapping or other confounding factors.
    • The treatment plan specifies the lowest appropriate number of additional sessions needed to complete treatment.
    Denial Risk

    Failure to Meet Reintroduction Criteria

    Requests to reintroduce TMS after an acute treatment episode may be denied unless all reintroduction criteria are documented.

    • The patient met the initial-treatment guidelines and responded positively to the prior course: at least 50% improvement in depressive symptoms or at least 30% improvement in OCD symptoms on a standardized instrument.
    • Sufficient time has elapsed to establish a clinically meaningful increase in symptoms; symptoms have worsened by at least 50% from peak response, measured with the same standardized instrument.
    • Other appropriate treatment approaches, such as psychotherapy, pharmacotherapy, or ERP, are being used concurrently.
    • Standard symptom inventories such as Y-BOCS, PHQ-9, or HAM-D support assessment and response monitoring; their administration in this context is not psychological testing and may not be billed with CPT codes 96130-96139.
    The policy also addresses deep transcranial magnetic stimulation (dTMS)
    Standard course of TMS
    Weekly scheduleFive treatments per week for six weeks
    Initial treatment phaseThe first six weeks comprise 30 sessions
    Taper and totalA three-week taper follows—three treatments in week one, two in week two, and one in week three—for 36 treatments total